Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Evotec AG    EVT   DE0005664809

EVOTEC AG (EVT)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Evotec AG
Specializes in the discovery and development of new drugs

Evotec AG engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies.

It operates through the EVT Execute and EVT Innovate segments.

The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmes on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties.

The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations.

The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Number of employees : 2 178 persons.
Sales per Businesses
20162017Delta
EUR (in Million)%EUR (in Million)%
EVT Execute137.8583.8%213.7883% +55.08%
EVT Innovate26.6616.2%43.8517% +64.51%
Sales per Regions
20162017Delta
EUR (in Million)%EUR (in Million)%
Europe97.0659%---
United States65.8040%97.4937.8% +48.15%
Japan and Rest of the World1.651%---
Germany--30.7511.9%-
United Kingdom--26.8210.4%-
France--60.1823.4%-
Rest of the World--42.3916.5%-
Managers
NameAgeSinceTitle
Werner Lanthaler, PhD502009Chief Executive Officer
Wolfgang Plischke, PhD672014Chairman-Supervisory Board
Mario Polywka, PhD552004Chief Operating Officer
Enno Spillner, MBA482016Chief Financial Officer
Cord E. Dohrmann, PhD542010Chief Scientific Officer
Claus Tycho Bræstrup, MD732013Independent Member-Supervisory Board
Bernd Hirsch482013Vice Chairman-Supervisory Board
Iris Löw-Friedrich MD, PhD582014Independent Member-Supervisory Board
Elaine Sullivan, PhD582015Member-Supervisory Board
Michael Shalmi MD, MBA532017Member-Supervisory Board
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 147,547,269 133,897,354 90.7% 249,915 0.2% 90.7%
Shareholders
NameEquities%
Novo Nordisk Fonden 14,767,926 10.0%
Roland Oetker 13,510,453 9.16%
Deutsche Asset Management Investment GmbH 8,852,462 6.00%
Allianz Global Investors GmbH 5,798,851 3.93%
Norges Bank Investment Management 3,700,512 2.51%
The Vanguard Group, Inc. 3,233,474 2.19%
BlackRock Asset Management Deutschland AG 1,661,842 1.13%
Principal Global Investors LLC 1,588,731 1.08%
JPMorgan Asset Management (UK) Ltd. 1,463,482 0.99%
BlackRock Fund Advisors 1,235,917 0.84%
Holdings
NameEquities%Valuation
Evotec AG (EVT) 249,9150.17%4,299,500 USD
Company contact information
Evotec AG
Manfred Eigen Campus
Essener Bogen 7
Hamburg 22419

Phone : +49.40.56081.0
Fax : +49.40.56081.222
Web : www.evotec.com
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalization (M$)
EVOTEC AG29.04%2 885
CELLTRION, INC.--.--%32 245
IQVIA HOLDINGS INC13.49%22 746
LONZA GROUP8.17%21 355
INCYTE CORPORATION-25.97%14 861
SEATTLE GENETICS, INC.31.33%11 158
ALNYLAM PHARMACEUTICALS, INC.-16.62%10 682
QIAGEN19.37%8 527
NEKTAR THERAPEUTICS0.00%8 412
EXACT SCIENCES CORPORATION28.70%8 242
SAGE THERAPEUTICS INC2.34%7 844
ICON PLC24.96%7 442
ALKERMES PLC-17.71%7 020
PRA HEALTH SCIENCES INC12.57%6 485
CHARLES RIVER LABORATORIES INTL. INC13.54%5 851
BIO-TECHNE CORP20.74%5 782
IONIS PHARMACEUTICALS INC-7.55%5 754
UNITED THERAPEUTICS CORPORATION-15.49%5 403
GALAPAGOS15.65%5 399
GALAPAGOS NV (ADR)14.37%5 399
FIBROGEN INC37.24%5 379
Connections : Evotec AG
Xellia Holdco A/S
Walter Siegenthaler Gesellschaft
Paul Ehrlich-Foundation
Robert Koch Stiftung eV
Technology Academy Finland
German Asia Pacific Business Association
University of Hohenheim
European Chemical Industry Council
Bayer Innovation GmbH
Bundesverband der Deutschen Industrie e.V.
IOLTECH SA
Exscientia Ltd.
Bertelsmann, Inc.
Forge Therapeutics, Inc.
ERT, Inc. /PA/
Evotect (India) Pvt Ltd.
Topas Therapeutics GmbH
Johann Wolfgang Goethe-Universität Frankfurt am Main
Bankinvest Biomedical Venture
Bayer Real Estate GmbH
The Royal Danish Scientific Society
Helmholtz-Gemeinschaft Deutscher Forschungszentren eV
German Chemical Industry Fund
SYNLAB Ltd.
Penguin Random House LLC
Momentum Gruppen A/S
Penguin Random House Ltd.
Bayer Technology Services GmbH
Hoechst Marion Roussel, Inc.
IP Group Plc /Venture Capital/
Concentro Management AG
Carrick Therapeutics Ltd.
Biom Venture Capital GmbH & Co. Fonds KG
FSHD Unlimited Cooperatie Ua
Novo Principal Investments
Eternygen GmbH
Aerocrine AB
Synlab International GmbH
ERT Holdco A/S
Ataxion, Inc.
Novo Invest 1 A/S
© 2018 People , Fundamentals and Ownership